Remove 2004 Remove Healthcare Remove Pharma
article thumbnail

A glance back to Pharma Integrates, London 2022 – part ii

pharmaphorum

Run by Life Science Integrates, Pharma Integrates was in its 11th year in 2022. Nonetheless, she also mentioned that, over the summer, Lord Prior had written an article published in the British Medical Journal entitled ‘Precision public health must be at the centre of modern healthcare’. Highly unlikely.”

Pharma 96
article thumbnail

Pharma responds to proposed EU pharmaceutical legislation reform

European Pharmaceutical Review

Pinsent Masons Charlotte Weekes, Senior Associate at Pinsent Masons shared with EPR : “The Commission’s ambitious pharma legislation review is the first significant review of the European system since 2004.” “It "Our concern is that the pharma legislation is not there yet."

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New Prescription Migraine Drugs Aren’t Resonating with Patients—Here’s How Pharma Can Boost Uptake

PM360

These low adoption rates highlight the need for more migraine-drug awareness and suggest that pharma marketers should explore new strategies to boost patient uptake. Patient self-advocacy is another powerful tool pharma marketers can leverage to stand out in the crowded market space and increase brand adoption.

article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

Furthermore, by simulating real-life scenarios, AR offers the chance for staff in the pharma industry to practice complex operations without the associated risks. When it comes to recruitment, the pharmaceutical industry should be well placed to capitalise on a society that now has healthcare front of mind. Raising the profile.

article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The revision process is reviving old conflicts in the pharma industry over fair and affordable access to medicines versus Europe’s status as a competitive home for pharma innovation.

Pharma 64
article thumbnail

Specialty pharma’s next big opportunity: it’s time for patient access to adopt an open protocol

pharmaphorum

Along their journey, specialty pharma patients interact with a series of siloed institutions: clinics, specialty pharmacies, copay program vendors, patient assistance programs, nurses, etc. To diagnose the problem facing specialty pharma, a brief history lesson is in order. Visa’s attempted $5.3 Many are still making the transition.

article thumbnail

Realising milestones with gene therapy for SMA

European Pharmaceutical Review

percent of Europe’s annual healthcare spend. In 2015, she joined Astellas Pharma, Northbrook, IL, and served as Global Lead for Immunology, CNS and Neuromuscular Indications and eventually as Global Medical Lead for the Muscle TA. References Pharma spending per capita; 3.8% Stakeholder education is critical to achieving this.